Novartis Stock

Novartis P/B

The P/B (Price-to-Book Ratio) of Novartis (NOVN.SW) as of Aug 13, 2026 is 8.25. In the previous year, P/B (Price-to-Book Ratio) was 8.63 — a change of -4.45% (lower).

P/B

8.25

YoY

-4.45%

Last updated:

P/B (Price-to-Book Ratio) of Novartis is 2026 8.25 . P/B (Price-to-Book Ratio) of Novartis was 2025 8.63 . It decreases by -4.45% lower compared to the previous year.
Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

P/B (Price-to-Book Ratio) of Novartis is 8.25 in 2026.

P/B (Price-to-Book Ratio) of Novartis changed from 8.63 to 8.25, representing a -4.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Novartis since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Novartis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Novartis

All Key Metrics — Novartis